The primary goal of the PPTC is to identify new agents that have the potential for significant activity when clinically evaluated against selected childhood cancers.
The Pediatric Preclinical Testing Consortium (PPTC) is a comprehensive program to systematically evaluate new agents against childhood solid tumor and leukemia models. The PPTC is supported through an NCI research contract to The Research Institute at Nationwide Children’s Hospital with Dr. Peter Houghton as the Principal Investigator. Testing occurs at The Research Institute and subcontract sites with expertise in specific childhood cancers.
The consortium is based on a substantial body of data showing that appropriate childhood cancer preclinical in vivo models can recapitulate known effective agents’ anti-tumor activity and can prospectively identify novel agents subsequently shown to have clinical activity against specific cancers of children and adolescents. By facilitating the development of a more reliable pediatric new agent prioritization process, the Pediatric Preclinical Testing Consortium will contribute to the goal of identifying more effective treatments for children with cancer.
PPTP Principal Investigators
- Dr. Peter Houghton, PhD
Greehey Children’s Cancer Research Institute
- Dr. E. Anders Kolb, MD
A. I DuPont Children’s Hospital, Wilmington
- Dr. Richard Gorlick, MD
Children’s Hospital at Montefiore, Albert Einstein College of Medicine
- Dr. Stephen Keir, PhD
Preston Robert Tisch Brain Tumor Center, Duke University
- Dr. John Maris, MD
Children’s Hospital of Philadelphia
- Dr. Richard Lock, PhD
Children’s Cancer Institute, Randwick, Australia
- Dr. C. Patrick Reynolds, MD, PhD
Texas Tech University Health Science Center, Lubbock